Navigation Links
Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
Date:9/15/2009

THE WOODLANDS, Texas, Sept. 15 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus. LX4211 is an orally-delivered, small molecule drug candidate that inhibits the sodium glucose transporter 2 (SGLT2). LX4211 is Lexicon's fourth drug candidate currently being tested in Phase 2 clinical trials.

"LX4211 offers an opportunity to treat diabetes by increasing urinary glucose excretion through a mechanism of action that is expected to avoid some of the disadvantages of existing diabetes drugs that result in storage of excess glucose," said Brian P. Zambrowicz, Ph.D., executive vice president and chief scientific officer at Lexicon. "By contrast, LX4211 through inhibition of SGLT2 has the potential to reduce caloric load and thereby enhance overall glucose homeostasis in patients with type 2 diabetes."

In the recently completed Phase 1 clinical trial in normal healthy volunteers, LX4211 was well tolerated at all dose levels and produced a dose-dependent increase in urinary glu
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
2. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
3. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
6. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Shire Completes Submission of NDA for Velaglucerase Alfa for Type 1 Gaucher Disease and Reports Positive Results for Remaining Two Phase III Trials
9. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
10. CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
11. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... VEGAS , Jan. 23, 2015 Cord Blood America, ... ) ("CBAI" or the "Company")  filed a Preliminary Proxy Statement, ... www.sec.gov ) today, and provides an update for shareholders detailing ... shares is requested. Dear Shareholders, As ...
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
(Date:1/23/2015)... Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the development and sale of patented biopharmaceutical medicine, ... pharmaceutical ingredients (API) today announced the business and development ... 1. Following the September 2014 JCM application ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... Company announces the recent formation of Alamo ... wholly owned subsidiary of Mission, will provide ... resources (HR) support.  Alamo will be headquartered ... States presence, which also includes the company,s ...
... Jan. 26, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... Laboratories, Inc.- Florida has reached a settlement with ... Watson,s generic versions of Mallinckrodt,s Exalgo® (Hydromorphone Hydrochloride ... December 10, 2010 in the United States District ...
Cached Medicine Technology:Mission Pharmacal Launches Alamo Pharma Services 2Mission Pharmacal Launches Alamo Pharma Services 3Watson Reaches Settlement with Mallinckrodt Over Exalgo(R) 2
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
Breaking Medicine News(10 mins):Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... reveals racial disparities, troublesome drug side effects , , THURSDAY, ... first annual Breast Cancer Symposium shed light on racial ... can affect survival, and how nagging side effects cause ... in San Francisco, is co-sponsored by the American Society ...
... Stars, Nation,s ... Sept. 6 Consumer,selection of foods that offer more ... don,t in many aisles of Hannaford Supermarkets --,in some ... data in the year,since the company launched Guiding Stars, ...
... Mylan Laboratories Inc.,(NYSE: MYL ) today announced that ... Food and Drug Administration for its,Abbreviated New Drug Application ... and 25 mg. Carvedilol Tablets are the generic ... of approximately $1.65,billion for the 12 months ending June ...
... N.Y., Sept. 5 Fairbank Farms, a national,ground ... Lean Ground Round Beef Patties. The ground beef ... been purchased by consumers in New,England on Wednesday ... of an abundance of caution, the product has ...
... starved environments have been used successfully to target ... according to scientists speaking today (Thursday 6 September ... Meeting at the University of Edinburgh, UK, which ... half of cancer sufferers our traditional treatments such ...
... Actavis Group, the,international generic pharmaceuticals company, ... the U.S. Food & Drug Administration to ... the product will commence,immediately. Carvedilol tablets, ... be available in 3.125, 6.25, 12.5 and ...
Cached Medicine News:Health News:Studies Shed New Light on Breast Cancer, Treatment 2Health News:Studies Shed New Light on Breast Cancer, Treatment 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 2Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 4Health News:Bacteria successful in cancer treatment 2Health News:Actavis Launches Carvedilol Tablets in the U.S. 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... Acuity Meter (RAM) is the first visual examination ... RETINAL ACUITY in eyes with glaucoma, cataract, and ... and can test each eye easily in under ... tested at Columbia University in New York City, ...
Versatility of the DFS Standard Fixator provides unsurpassed below-the-ring correction of angular, rotational and translational deformities. Length discrepancy can be precisely corrected in 1/4mm inc...
... Ace Align is an external fixator designed ... of the femur, tibia, humerus and forearm. ... where external fixation is the treatment of ... ,The Ace Align is fully compatible with ...
Medicine Products: